Investors of Novo Nordisk A/S Urged to Join Class Action on Misleading Statements
Attention Novo Nordisk A/S Investors
If you are an investor in Novo Nordisk A/S (NYSE: NVO), you should be aware that The Gross Law Firm is currently addressing an important class action lawsuit. The firm is reaching out to those who purchased Novo Nordisk shares during a specific class period. The deadline for serving as a lead plaintiff in this case is September 30, 2025, and shareholders need to act quickly to ensure they are protected.
Understanding the Allegations
The lawsuit highlights serious claims against Novo Nordisk, asserting that the company provided overly optimistic assertions to investors while simultaneously concealing critical negative information. Claims detail that Novo overstated its growth potential and the market opportunity, particularly regarding the use of compounded GLP-1 drugs and the competitive landscape. These issues became apparent when Novo lowered its sales and profit outlook shortly after announcing disappointing results for the second quarter of fiscal year 2025.
On July 29, 2025, the company disclosed its downward revision regarding sales forecasts due to a variety of factors, including continued reliance on compounded GLP-1 medications and slower-than-expected expansions in the market. Following this announcement, Novo's stock price fell significantly from $69 per share to $53.94 in a single trading day, marking a substantial decline of approximately 21.83%.
Key Dates and Next Steps
- - Class Period: This lawsuit encompasses shares purchased between May 7, 2025, and July 28, 2025.
- - Deadline for Lead Plaintiff: Shareholders interested in taking a more active role in this class action must register by September 30, 2025.
The Gross Law Firm is committed to assisting those impacted by potential securities fraud, and it is essential for shareholders to register their interests promptly. Once registered, you'll gain access to tracking software to keep you informed about the lawsuit’s progress.
Why Choose The Gross Law Firm?
The Gross Law Firm is known nationwide for its dedication to protecting the rights of investors and ensuring transparency in corporate practices. They primarily target companies that engage in misleading or fraudulent practices that may lead to unjustified inflation of stock values, causing investors to incur significant losses.
If you're a shareholder of Novo Nordisk and have purchased shares during the class period, it's crucial to reach out to the firm for guidance and support. Please visit their website to complete the registration form and to learn more about your rights and potential recovery options.
Contact Information
For more information and to register your interest in the class action lawsuit, you can contact:
- - The Gross Law Firm
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
In conclusion, if you have been affected by the alleged misstatements and misleading practices of Novo Nordisk A/S, do not hesitate to secure your position in this lawsuit. The upcoming deadline is imperative for asserting your rights as an investor, and those interested must act swiftly.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.